Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ta-Len-Tra
2024-516408-40-00Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Proportion of patients with TACE failure treated with lenvatinib who undergo liver transplantation. Started Oct 2024; status: completed.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-516408-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516408-40-00.